We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Probiotics Against Pathogenic Bacteria in Connection With Anaesthesia

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01521650
First Posted: January 31, 2012
Last Update Posted: October 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Lund University
Information provided by (Responsible Party):
Bengt Klarin, Region Skane
  Purpose

Longer surgical procedures require intubation and there is a potential risk of contaminating the lower airways with pathogenic bacteria from the mouth and oropharynx.

Healthy people seldom have pathogenic bacteria originating from the gastro-intestinal canal but those do occur among patients, both in those not so sick and patients with more severe problems.

For ICU patients we have seen a reduction of emerging enteric bacteria in patients given oral care with probiotics and this is a pilot study to explore the possibility of the same kind of positive effects in patients due for longer (more than 4 hours of anesthesia) procedures.

Randomisation

  • No prophylaxis
  • Preparation with a probiotic suspension before intubation.

Cultures

  • oropharynx

    • before treatment
    • after intubation
    • before extubation
    • day 1 postoperatively
  • tracheal secretions

    • after intubation
    • before extubation

Condition Intervention
Oropharyngeal Microbiology Dietary Supplement: Probiotics

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Probiotics for Reduction of Colonisation With Pathogenic Bacteria in the Oropharynx in Connection With Anaesthesia

Resource links provided by NLM:


Further study details as provided by Bengt Klarin, Region Skane:

Primary Outcome Measures:
  • Differences in pathogenic bacteria in the oropharynx and lower airways [ Time Frame: During hospitalization, up to 4 weeks ]
    Emerging and resident bacteria will be compared for the cultures taken in the oropharynx and from tracheal secretions in conection with anaestesia and a surgical intervention


Secondary Outcome Measures:
  • White blood cells [ Time Frame: During hospitalization, up to 4 weeks ]
    WBC taken pre-op and days 1,2,3 post-op

  • CRP [ Time Frame: During hospitalization, up to 4 weeks ]
    CRP taken pre-op and days 1,2,3 post-op

  • Pneumonia [ Time Frame: Up till 7 days postoperatively ]
    X-ray verified infiltrations in combination with expectorates

  • Length of hospital stay [ Time Frame: time to discharged from hospital or patients death ]
    Comparison of length of stay between the intervention group and the control group


Estimated Enrollment: 102
Study Start Date: January 2012
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Probiotics
Patients will gurgle and swallow a mixture of probiotic bacteria
Dietary Supplement: Probiotics
Patients will gurgle and swallow a mixture of probiotic bacteria
Other Names:
  • Lactobacillus plantarum 299
  • Lactobacillus plantarum 299v
No Intervention: Control
No intervention. What has been the standard procedure so far

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients
  • Planned interventions
  • Anaesthesia > 4 hours and requiring intubation

Exclusion Criteria:

  • Ulcers in the mouth, oropharynx, oesophagus and stomach
  • Current infections in the airways
  • Known immuno deficiences
  • Emergency cases
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01521650


Locations
Sweden
Lund University Hospital
Lund, Sweden, SE-22185
Sponsors and Collaborators
Region Skane
Lund University
Investigators
Principal Investigator: Bengt klarin, MD PhD Lund University
  More Information

Publications:
Responsible Party: Bengt Klarin, MD Consultant, Region Skane
ClinicalTrials.gov Identifier: NCT01521650     History of Changes
Other Study ID Numbers: ProAnest
First Submitted: January 26, 2012
First Posted: January 31, 2012
Last Update Posted: October 4, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Results are intended to be published in a scientific journal

Keywords provided by Bengt Klarin, Region Skane:
Probiotics
Anaesthesia
Intubation
Pathogenic bacteria

Additional relevant MeSH terms:
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs